Platelets can contain SARS-CoV-2 RNA and are hyperactivated in COVID-19

Younes Zaid PhD^{1,2,3,#}, Florian Puhm PhD^{4,5,#}, Isabelle Allaeys PhD^{4,5}, Abdallah
Naya PhD³, Mounia Oudghiri PhD³, Loubna Khalki PhD⁶, Youness Limami PhD¹,
Nabil Zaid PhD², Khalid Sadki PhD², Rafiqua Ben El Haj PhD¹, Wissal Maher PhD¹,
Belayachi Lamiae PhD¹, Bouchra Belefquih MD¹, Amina Benouda MD¹, Amine
Cheikh PharmD¹, Yahia Cherrah PharmD¹, Louis Flamand PhD^{4,5}, Fadila Guessous
PhD^{6,*}, Eric Boilard PhD^{4,5,*}
¹Research Center of Abulcasis University of Health Sciences, Cheikh Zaïd Hospital,

- 11 Rabat, Morocco
- ¹²²Biology Department, Faculty of Sciences, Mohammed V University, Rabat, Morocco
- ¹³³Immunology and Biodiversity Laboratory, Department of Biology, Faculty of ¹⁴Sciences Ain Chock, Hassan II University, Casablanca, Morocco
- ⁴Centre de Recherche du Centre Hospitalier Universitaire de Québec- Université
 Laval, Canada
- ⁵Département de microbiologie-infectiologie et d'immunologie, Université Laval, QC,
 Canada
- ¹⁹ ⁶Research Center, Mohammed VI University of Health Sciences (UM6SS), 20 Casablanca, Morocco
- ²⁰ ⁴ Contributed equally
- 22 * Corresponding Authors
- 23 **Short title:** Platelet functions in COVID-19

24 **Corresponding authors**:

25 Eric Boilard, PhD, Centre de Recherche du Centre Hospitalier Universitaire de

- 26 Québec, Faculté de Médecine de l'Université Laval and Centre de Recherche
- ARThrite, 2705 Laurier Blvd, room T1-49, Québec, QC, Canada G1V 4G2. E-mail
 Address: eric.boilard@crchudeguebec.ulaval.ca
- Fadila Guessous, PhD, Research Center, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco. E-mail Address: fguessous@um6ss.ma
- 31 **Subject terms:** Infectious diseases/Emerging infectious diseases, SARS-CoV-2,
- 32 COVID-19, Hematology, Platelets
- 33

35 **KEY POINTS**

36 Platelets are a source of inflammatory cytokines and degranulate in COVID-19

Platelets contain SARS-CoV-2 RNA molecules and are prone to activation in COVID-19

39

40 **ABSTRACT**

- Rationale: In addition to the overwhelming lung inflammation that prevails in COVID-19, hypercoagulation and thrombosis contribute to the lethality of subjects infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Platelets are chiefly implicated in thrombosis. Moreover, they can interact with viruses and are an important source of inflammatory mediators. While a lower platelet count is associated with severity and mortality, little is known about platelet function during COVID-19.
- 48 **Objective:** To evaluate the contribution of platelets to inflammation and thrombosis 49 in COVID-19 patients.
- Methods and Results: We document the presence of SARS-CoV-2 RNA in 50 51 platelets of COVID-19 patients. Exhaustive assessment of cytokines in plasma and in platelets revealed the modulation of platelet-associated cytokine levels in COVID-52 19, pointing to a direct contribution of platelets to the plasmatic cytokine load. 53 54 Moreover, we demonstrate that platelets release their alpha- and dense-granule contents and phosphatidylserine-exposing extracellular vesicles. Functionally, 55 platelets were hyperactivated in COVID-19 subjects, with aggregation occurring at 56 57 suboptimal thrombin concentrations. Furthermore, platelets adhered more efficiently onto collagen-coated surfaces under flow conditions. 58
- 59 **Conclusions:** These data suggest that platelets could participate in the 60 dissemination of SARS-CoV-2 and in the overwhelming thrombo-inflammation 61 observed in COVID-19. Thus, blockade of platelet activation pathways may improve 62 outcomes in this disease.
- 63
- 64 Key words (3 to 5): SARS-CoV-2; COVID-19; platelets; inflammation; cytokines

65 Non-standard Abbreviations and Acronyms

ACE2 ALT	Angiotensin Converting Enzyme 2 Aminotransferase
AST	Aspartate Aminotransferase
COVID-19	Coronaviruse Disease 2019
FDP	Fibrin Degradation Product
IL	Interleukin
LDH	Lactate Dehydrogenase
NET	Neutrophil-extracellular trap
PF4	Platelet Factor 4
PKC	Protein kinase C
PLR	Platelet-Lymphocyte Ratio
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
TLR	Toll-like receptor
TNF	Tumor Necrosis Factor
TxB2	Thromboxane B2

67 Introduction

The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, emerged in Wuhan of Hubei province in China in December 2019 and rapidly spread to more than 196 countries worldwide.^{1,2} The World Health Organization (WHO) declared the outbreak a serious public health emergency of international concern and by June 2020, the virus had infected over 7 million and killed more than 400 000 individuals worldwide.^{2,3}

75

SARS-CoV-2 is a positive-sense single stranded RNA virus.^{4,5} The main SARS-CoV-76 2 counter-receptor on human cells is the angiotensin converting enzyme 2 (ACE2), 77 highly expressed by nasopharyngeal airway epithelial cells as well as alveolar 78 79 epithelial cells, vascular endothelial cells and lung macrophages. The virus tropism likely explains the notorious respiratory symptoms observed during infection.^{6,7} An 80 uncontrolled systemic inflammatory response, known as the cytokine storm, results 81 from immune effector cell release of substantial amounts of pro-inflammatory 82 83 cytokines, such as tumor necrosis factor (TNF), interleukin (IL)-1, IL6, IL7 and granulocyte-colony stimulating factor (G-CSF),^{8,9} which are suggested to contribute 84 to SARS-CoV-2 lethality.^{1,10,11} While outstanding research aimed at understanding 85 SARS-CoV-2 pathogenesis initially focused on lung inflammation, COVID-19 also 86 implicates multi-organ damage, leading to multiple organ failure, notably of the 87 respiratory, cardiac, renal and hepatic systems.^{1,12} 88

89

Thrombotic complications that manifest as microvascular thrombosis, venous or 90 arterial thrombosis are features detected in most patients with multi- organ failure.¹³⁻ 91 92 ¹⁷ Disseminated intravascular coagulation (DIC) is a condition in which blood clots form throughout the body, blocking small blood vessels. Although DIC appeared 93 rarely and was associated with bleeding manifestations in a multicenter retrospective 94 study involving 400 COVID-19 patients (144 critically ill),¹⁷ DIC occurred in the 95 majority (71%) of patients who died of COVID-19 according to a study of 183 96 consecutive patients.¹⁸ What drives DIC during COVID-19 is currently unknown. It is 97 important to note that accumulating evidence shows that the blood of COVID-19 98 patients is hypercoagulable.^{14,17-20} Higher D-dimer and fibrin degradation product 99 (FDP) levels, a longer prothrombin time and activated partial thromboplastin time are 100 observed in SARS-CoV-2-infected patients with hospitalization complications or in 101 those who died, relative to survivors.^{17,18,20} 102

103

Hematological manifestation in symptomatic COVID-19 patients include severe 104 leukopenia and lymphopenia.^{14,18,21} Lower platelet counts are associated with 105 increased risk of in-hospital mortality in COVID-19 patients, although the platelet 106 levels are generally not considered as clinically-relevant as patients typically do not 107 require platelet transfusions.^{17,22-26} It is suggested that SARS-CoV-2 may reduce 108 platelet production, increase platelet destruction, or more likely that platelet 109 activation and thrombosis in patients may increase platelet consumption.²⁵ As 110 thrombosis and blood coagulation are chiefly controlled by platelets, it is critical to 111 define whether platelets are activated in COVID-19. 112

113

Platelets are small (2–4 µm in diameter) anucleated cells derived from megakaryocytes in bone marrow and lungs.^{27,28} Nearly one trillion platelets patrol the blood vessels to maintain the integrity of the vasculature. Damage to blood vessels triggers the formation of a thrombus to stop subsequent bleeding.²⁹ Thrombus
 formation mediated by platelets can also implicate extracellular vesicles
 (microparticles or microvesicles), which provide anionic phospholipids that can
 support the coagulation cascade.³⁰

121

In addition to their role in hemostasis and thrombosis, platelets also contribute to 122 immunity and inflammation.³¹⁻³³ The extravasation of neutrophils and their invasion 123 of inflamed tissues require their interaction with activated platelets.^{34,35} Moreover, the 124 liberation of neutrophil-extracellular trap (NETosis), a process by which neutrophils 125 release extracellular DNA, is observed in COVID-19.^{36,37} NETosis requires platelets 126 and may thus contribute to thrombosis.^{38,39} Platelets express immune and 127 inflammatory molecules such as interleukin-1 (IL1),40 and a set of immune receptors 128 including CD40L, Toll-like receptors (TLR),³¹ and the Fc receptor for IgG FcyRIIA⁴¹. 129

130

Viruses such as dengue and influenza can infect megakaryocytes, which leads to the 131 upregulation of type-I interferon genes.⁴² While dengue virus can replicate in 132 platelets,⁴³ influenza virus can be internalized by platelets and is transported through 133 the circulatory system in humans.⁴⁴ Influenza virus-induced lung injury in mice can 134 be prevented by targeting of platelet allbß3 by an antagonist or other anti-platelet 135 compounds such as clopidogrel, an antagonist of ADP receptors, or blockers of 136 protease-activated receptor-4, thus pointing to an active role by platelets in influenza 137 pathogenesis.⁴⁵ Influenza and herpes simplex virus-1 also activate platelet 138 aggregation and thrombosis due to the presence of prevalent opsonizing antibodies 139 and their interaction with FcyRIIA.^{46,47} Thus, activated platelets may contribute to 140 both the overwhelming inflammation and thrombosis that prevail in COVID-19. 141

142

While thrombosis and coagulation abnormalities predict worse outcomes in COVID-144 19, the role of platelet function has yet to be investigated. Here, we examined 145 platelet activation, secretion, adhesion and aggregation in patients with severe and 146 non-severe COVID-19 infection.

147

148 Methods

- 149 Supplement contains the detailed description of methods.
- 150

151 **Results**

152 **Patient screening and characterization**

A total of 1,544 patients with suspected SARS-CoV-2 infection (travelers, proximity 153 to infected patients and presence of symptoms) were screened according to the flow 154 chart presented in **Online Figure I**. The clinical symptoms included fever, cough, 155 dyspnea, fatigue, headache, chest pain and pharyngalgia. Initial screening in 156 addition to laboratory blood testing and high-resolution chest computed tomography 157 imaging (CT scans) (**Online Figure II**) led to the selection of 186 patients, who were 158 then screened for the presence of 2019-nCoV RdRp and E genes using RT-PCR 159 (Online Figure III) (see Table 1 and Online Figure IV for clinical data). The degree 160 of COVID-19 severity (severe vs non-severe) was defined at the time of patient 161 admission using the American Thoracic Society guidelines for community-acquired 162 pneumonia ⁴⁸. There were 71 cases in the non-severe COVID-19 (COVID-Non-163 Severe) group and 34 cases in the severe COVID-19 group (COVID-Severe), while 164 81 individuals were declared negative by both throat swab RT-PCR amplification of 165 2019-nCoV RdRp and E genes and chest CT scans. Among all COVID-19 positive 166

patients, the mean ages were 48.96 ± 17.96 and 57.15 ± 23.10 years for non-severe cases and severe cases, respectively. The hospitalization duration was significantly higher for severe patients (29.63 ± 2.74 days) compared with non-severe patients 18.27 ± 4.33 (days), with 8.5% of total patients critically ill and admitted to the Intensive Care Unit (ICU). Four COVID-Severe patient deaths occurred in the ICU, while all non-severe patients survived.

173

174 Blood parameters and thrombocytopenia

The severity of disease was established, and routine blood parameters were 175 monitored at the time of admission for both the non-severe and severe cases of 176 COVID-19 (Table 1 and Online Figure IV).² Lymphocyte counts, alanine 177 aminotransferase (ALT) and aspartate aminotransferase (AST) data were similar 178 179 between the 2 groups of infected patients. However, the lactate dehydrogenase (LDH) inflammation marker, which was higher than the expected normal range in 180 both groups, was significantly increased in severe COVID-19 patients in comparison 181 with non-severe patients, pointing to a possible cytokine storm associated with 182 183 disease severity (Table 1 and Online Figure IV).

184

Thus, we evaluated platelet numbers and platelet-to-lymphocyte ratios (PLR) 185 measured at the time of admission in the two groups. Platelet counts were in the 186 lower range in both COVID-19 severe (148.5 ± 10.1) and non-severe patients (208.0 187 ± 99.4) in comparison to the expected count in healthy individuals (130 - 400 X 188 189 10⁶/mL). Moreover, we observed a modest, but statistically significant reduction in platelet counts between the 2 patient groups. The PLR was lower in severe patients 190 compared with non-severe patients, arguing in favor of the thrombosis mainly 191 reported in more severe cases (Table 1 and Online Figure IV). 192

193

194 Platelets in COVID-19 patients can be associated with SARS-CoV-2 RNA

SARS-CoV-2 RNA has been identified in urine and stool samples in addition to 195 semen, consistent with expression of ACE2 outside the respiratory tract, such as in 196 endothelial cells that line blood vessels, heart, kidney and spermatozoa.⁵¹⁻⁵⁴ Whether 197 platelets express ACE2 in COVID-19 and contain SARS-CoV-2 RNA have never 198 been verified. Thus, platelets were isolated from recruited healthy individuals (n=17) 199 and from COVID-19 patients (38 non-severe and 11 severe) at the time of 200 admission, and we tested for the presence of RNA coding for SARS-CoV-2 RdRp 201 202 and E, and for ACE2. While no RNA from SARS-CoV-2 was detected in healthy subjects (0%), we detected SARS-CoV-2 RNA in platelets from non-severe (23.7%) 203 and severe (18.2%) COVID-19 patients. Both SARS-CoV-2 RdRp and E genes were 204 205 amplified equally (Table 2 and Online Figure VA), which might suggest that platelets contain viral particles. Conversely, ACE2 mRNA molecules were identified 206 in platelets of all individuals tested (10 individuals/group) (Table 2 and Online 207 Figure VB). The data suggest that platelets may disseminate SARS-CoV-2 RNA 208 molecules. 209

210

211 Circulating cytokines

Elevated inflammatory cytokine levels are reported in the blood of COVID-19 patients^{8,9} and may contribute to the overwhelming inflammation and to coagulation through the activation of endothelial cells.^{55,56} We used a multiplex assay to monitor 48 cytokines in plasma prepared from healthy individuals (n=10) and from COVID-19 patients (10 non-severe and 9 severe) at the time of admission. With the exception

of 12 cytokines/chemokines that were unchanged (IL-1α, IL-4, IL-5, IL-8, IL-10, IL-217 12p70, IL-15, MIP1 α, MCP-1, CXCL9, IL-25, RANTES), and IL-3 the concentration 218 of which was significantly reduced in COVID-19 (non-severe and severe), we 219 identified 35 cytokines that were significantly elevated, including TNF, IL-1, IL-6, 220 interferon (IFN) α and γ , and eotaxin (Figure 1 and Online Figure VI). Soluble 221 CD40L, as well as growth factors such as granulocyte colony-stimulating factor (G-222 CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), fibroblast-223 growth factor 2 (FGF-2), platelet-derived growth factor (PDGF) and vascular 224 endothelial growth factors (VEGF) were also significantly increased in COVID-19 225 (Figure 1 and Online Figure VI). 226

227

228 Platelets produce inflammatory cytokines in COVID-19

229 We then determined the ability of COVID-19 patient platelets to produce inflammatory mediators. Platelets derived from healthy individuals and from severely 230 and non-severely affected patients were stimulated with low doses of a-thrombin 231 (0.025 and 0.05 U/mL). Platelets were then lysed, and the amounts of IL-1 β , IL-18, 232 233 sCD40L and the eicosanoid thromboxane B₂ (TxB₂) were determined. While IL-18 secretion and thromboxane production were unaffected in the disease, we found that 234 COVID-19 platelets were more potent at producing IL-1β and soluble CD40L upon 235 exposure to 0.05 U/mL of thrombin in comparison with healthy subjects (Figure 2A). 236 Platelets from all subjects were similarly efficient at releasing the inflammatory 237 mediators when higher concentrations of thrombin were used, suggesting that 238 239 platelets are a source of inflammatory mediators and may be primed to release certain inflammatory molecules during SARS-CoV-2 infection. 240

241

Because they are anucleated, the platelet cytokine content can mirror that of 242 megakaryocytes, or may be regulated by translation upon platelet activation.⁵⁷ 243 However, nothing is known regarding the platelet cytokine content in COVID-19. 244 Thus, we monitored cytokines in lysates prepared using platelets from COVID-19 245 patients and included healthy subjects as controls. While a few cytokines were below 246 the detection limit (G-CSF, IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, IL-22, TGF α and 247 VEGF), we detected 36 cytokines in platelets from healthy individuals, including 248 CD40L, IFN α and y and IL-1 β (Figure 2B and Online Figure VI), in agreement with 249 their important cytokine content. Of note, we found significantly reduced levels for 17 250 cytokines, including cytokines relevant to virus and inflammatory responses (e.g. 251 252 sCD40L, eotaxin, IFN α and γ , IL1 β , TNF α and β) (Figure 2B and Online Figure VI) in COVID-19. Together, the data show that platelets are primed to generate 253 254 certain cytokines and release their cytokine cargo during SARS-CoV-2 infection.

255

256 Platelets degranulate in COVID-19

Platelet alpha- and dense-granule content, determined by the assessment of PF4 and serotonin respectively, was examined in platelets. We found a reduction in both PF4 and serotonin in platelets from non-severe and severe COVID-19 patients in comparison with healthy individuals (**Figure 3A**). Moreover, robust increases in PF4 and serotonin levels were measured in plasma from COVID-19 patients, independent of disease severity (**Figure 3B**), thereby suggesting that platelets degranulate during SARS-CoV-2 infection.

264

266 Platelets release extracellular vesicles in COVID-19

Extracellular vesicles (EV) released by platelets can participate in both inflammation 267 and the coagulation process due to the exposure of phosphatidylserine^{30,58,59}. 268 However, it is currently unknown whether EV are produced in COVID-19. EV smaller 269 than 1 µm and of platelet origin identified by the surface expression of CD41 were 270 detected by high sensitivity flow cytometry. To determine whether EV expressed 271 surface phosphatidylserine, we included annexin V conjugated with a fluorescent 272 probe in the analyses. EV were sensitive to detergent treatment, which confirmed 273 their membrane moiety. Moreover, no annexin V⁺ EV were detected when Ca²⁺ ions 274 were chelated by ethylenediaminetetraacetic acid (EDTA), which further ensured the 275 specificity of the detection approach (**Online Figure VII**). We found a statistically 276 significant increase in platelet-derived EV and in phosphatidylserine-exposing 277 278 platelet EV in COVID-19 patients in comparison with healthy subjects (Figure 4). The levels of both types of EV were similar in non-severe and severe COVID-19 279 280 patients.

281

282 Platelets are hyperactivated in COVID-19

Platelet activation is a complex balance of positive and negative signaling pathways 283 involving several protein kinase C (PKC) isoforms expressed in human platelets. 284 Among these kinases, PKC δ is a key regulator of platelet granule secretion, 285 activation and aggregation activity.^{60,61} To determine whether PKCδ is involved in 286 platelet activation during this infection, platelets collected from severe and non-287 288 severe patients were stimulated (or not) with a low dose of α -thrombin (0.05 U/mL), lysed and then analyzed for the presence of phosphorylated-PKCδ Tyr³¹¹. We found 289 that PKCδ phosphorylation on Tyr³¹¹ residue was significantly increased in response 290 to a low dose of α -thrombin in patients with severe (p < 0.01) and non-severe (p < 291 0.05) COVID-19 infection, while phosphorylation was undetectable in controls. 292 Phosphorylation of PKC δ was also significantly increased in severe patients in 293 comparison with non-severe patients (Figure 5), thus suggesting that platelet 294 activation signaling pathways may be upregulated in the disease. 295

296

The relationship between platelet activation and the severity of COVID-19 was then 297 investigated by functional assays. Platelets from severe and non-severe COVID-19 298 299 patients were collected and analyzed by optical aggregometry under arterial flow conditions using various doses of a-thrombin. Platelets exposed to suboptimal 300 301 concentrations of α -thrombin (0.05 U/mL) were highly activated (\geq 2.5-fold increase) in both severe and non-severe patients compared with controls (Figure 6A and 6B). 302 When platelets from all groups were stimulated with a higher concentration of a-303 304 thrombin (2 U/mL), no differences were observed, pointing to a lower platelet stimulation threshold in COVID-19 patients (Figure 6A and 6B). Moreover, the 305 formation of platelet aggregates was visualized bv rhodamine-based 306 immunofluorescence on a collagen-coated surface under flow conditions, and the 307 ratio of adherent platelets to total platelets (activated vs non-activated platelets) was 308 calculated. The number of adherent platelets was significantly higher in severe 309 patients compared with non-severe patients and controls, implying the involvement 310 of the thrombotic events in the disease magnitude (Figure 6C). 311

- 312
- The results are visualized in a graphical summary in **Figure 7**.
- 314
- 315

316 **Discussion**

Both inflammation and thrombosis are clinical manifestations observed during 317 SARS-CoV-2 infection. They can be lethal, and the understanding of cellular and 318 molecular effectors in COVID-19 may reveal novel therapeutic approaches, critical 319 for the treatment of patients whilst vaccines are still lacking. Platelets can interact 320 with viruses and can participate in both inflammation and thrombosis. Thus, for this 321 study, we examined platelets in a cohort of non-severe and severe COVID-19 322 patients with confirmed lower range (but not thrombocytopenic) platelet counts, in 323 agreement with the current literature.²²⁻²⁶ Our findings identify SARS-CoV-2 RNA in 324 patient platelets and reveal that platelets express pro-inflammatory molecules and 325 are hyperactivated in COVID-19. 326

327

Spike glycoprotein S mediates SARS-CoV-2 attachment to the cellular receptor 328 ACE2 and entry by fusion of the viral envelope with cell membranes.⁶² We detected 329 ACE2 mRNA in platelets, which may contribute to the potential entry of the virus in 330 platelets if translated and expressed. Of interest, was the detection of SARS-CoV-2 331 332 RNA in platelets from some COVID-19 patients. However, it remains to be established whether platelets represent target cells susceptible to infection or 333 whether platelets might have captured circulating SARS-CoV-2 RNA molecules. 334 Alternatively, megakaryocytes that produce platelets, may be susceptible to SARS-335 CoV-2 infection and transfer viral RNA as pro-platelets are produced. The presence 336 of viral RNA in platelet cytosol may activate platelet TLR-7, a process that occurs in 337 338 cases of influenza and encephalomyocarditis virus infections.^{44,63}

339

Influenza virus and herpes simplex virus-1 (HSV-1) can trigger platelet degranulation 340 when antibodies opsonize viral particles, and thereby activate platelet FcvRIIA.46,47 341 While antibodies specifically directed at SARS-CoV-2 are not expected in most 342 individuals at an early stage of the pathogenesis, they might be produced at a later 343 stage of infection, or prevailing cross-reacting antibodies against other more 344 common coronaviruses that generate minor cold symptoms in humans (229E, NL63, 345 OC43 and HKU1) may suffice to form immune complexes and activate platelet 346 FcyRIIA.^{4,5} Thus, differences in antibody profiles, especially in neutralizing 347 antibodies, among severe and non-severe COVID-19 patients may contribute to 348 platelet interaction with the virus, and to the overwhelming inflammation. With the 349 dissemination of the SARS-CoV-2 virus in the population, possible re-infections and 350 351 vaccination, the activation of platelet FcyRIIA due to the presence of SARS-CoV-2 antibodies may be even more relevant in subsequent years. 352

353

354 SARS-CoV-2 entry into endothelial cells, which express ACE2, and the loss of endothelium integrity may favor recruitment of circulating platelets to sites of 355 infection, their activation and degranulation, suggesting that the inhibition of 356 endothelial cell activation may improve disease outcome.⁶⁴ Megakaryocytes in lungs 357 bear an immune profile distinct from the megakaryocytes found in bone marrow.²⁸ 358 While it is unknown if lung megakaryocytes express ACE2 protein, lung 359 megakaryocytes may be infected, thereby leading to generation of virus-containing 360 platelets in lungs. Moreover, dengue and influenza viruses can infect megakaryocytes, which impacts the megakaryocyte transcriptome.⁴² Hence, 361 362 platelets produced by infected megakaryocytes, and/or by megakaryocytes in the 363 inflamed environment, may present a different transcriptome, which may explain 364

their potency at producing inflammatory cytokines, such as IL-1, when activated by α -thrombin.

367

From platelet degranulation and cytokine release analyses, we concluded that 368 platelets can contribute to the cytokine storm reported in COVID-19. Only a limited 369 number of cytokines (Gro α, IL-7, IL-12p40, PDGF AA/BB) were found significantly 370 increased in platelets in COVID-19, which may be due to their over-expression by 371 platelets or megakaryocytes, or to their abundance in the environment and their 372 capture by platelets. While molecules such as CD40L, PF4 and serotonin are 373 abundant in platelet granules and are released upon degranulation, cytokines such 374 as IL-1 may be produced *de novo* following platelet activation.⁵⁷ Therefore, the 375 presence of CD40L, PF4 and serotonin are clear indicators of platelet degranulation 376 377 *in vivo*. The molecules secreted by platelets can have effects on numerous cell types as well as the vasculature. Serotonin for instance, which we found to be abundantly 378 released in this disease, can directly impact blood vessel integrity and promote 379 leukocyte recruitment and cytokine release. 46,65 Of potential relevance, soluble 380 CD40L, which we found to be released by platelets in COVID-19, can contribute to 381 both activation of CD40 bearing cells and thrombosis by stabilizing glycoprotein 382 allbβ3.⁶⁶ This may not be unique to SARS-CoV-2 as dengue virus also induces the 383 release of CD40L from human platelets.⁶⁷ 384

385

We made the original observation that platelets release extracellular vesicles (EV) in 386 this disease. While EV, with their expression of phosphatidylserine can contribute to 387 coagulation and thrombosis, they can also transport molecules from the mother 388 platelets.⁵⁸ EV could transport platelet-derived cytokines, as well as other pro-389 390 inflammatory molecules such as damage associated molecular patterns (DAMPs) reportedly transported by EV from activated platelets.^{58,68,69} The fact that platelets 391 are activated in both non-severe and severe patients may explain the lower platelet 392 counts observed in both cohorts of COVID-19 patients. As platelet degranulation and 393 the release of EV were similar in both non-severe and severe COVID-19 patients, 394 the contribution of other players that lead to severe manifestations of the disease is 395 expected. Thus, therapeutic approaches to treatment of COVID-19 may require a 396 combination of drugs targeting platelet activities or platelet-derived molecules in 397 addition to medications directed against other inflammatory sources. 398

399

400 Using functional assays, we observed that platelets from COVID-19 patients are activated and hyperresponsive. Platelets were more efficiently at producing 401 inflammatory cytokines, and they aggregated and adhered to a collagen surface 402 403 more efficiently when originating from COVID-19 patients. As such, hyperactivation of platelets may contribute to the disease pathogenesis through both the release of 404 inflammatory mediators and thrombosis. This could explain the lower platelet count 405 and importantly, may contribute to the thrombo-inflammatory state associated with 406 407 COVID-19 infection. In summary, our study has revealed that SARS-CoV-2 infection causes platelet activation resulting in increased systemic inflammatory mediator 408 409 production and platelet aggregation, two main clinical symptoms associated with COVID-19. The blockade of platelet activation pathways may improve the outcomes 410 in this disease. 411

- 412
- 413

Acknowledgments 414

We are grateful to the patients and the members of the COVID-19 laboratory of 415 Cheikh Zaid Hospital in Rabat for their technical assistance with the RT-PCR tests, 416 laboratory blood tests and the patients' clinical data collection. YZ, FG and EB 417 conceived the initial concept and designed the study. FP, IA, AN, MO, LK, YL, NZ, 418 KS, RBE, BB, AC and YC participated to design the study, performed experiments 419 and were involved in the data extraction. WM, LB and AB contributed critical 420 reagents, biospecimens and instruments. EB, YZ, FP, IA, LF and FG wrote the 421 manuscript and all authors read and approved the final manuscript. 422

423

Sources of Funding: 424

This study was supported by Cheikh Zaid Foundation and the Canadian Institutes of 425 426 Health Research (to LF). EB is recipient of senior award from the Fonds de Recherche du Québec en Santé (FRQS). FP is recipient of a postdoctoral fellowship 427 from FRQS. 428

429

430 **Ethics Statement**

This study was approved by the Local Ethics Committee of Cheikh Zaid Hospital, 431 Rabat, Morocco.

- 432
- 433

Supplemental Materials 434

- **Expanded Materials & Methods** 435
- 436 Online Figures I – VII
- References 2, 48-50 437
- 438
- **Disclosures:** 439
- 440 None.
- 441
- 442

443 **References**

Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19:
immunity, inflammation and intervention. *Nat Rev Immunol.* 2020.

446 2. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease
447 2019 in China. *N Engl J Med*. 2020;382(18):1708-1720.

448 3. <u>https://covid19.who.int</u> CdC-WhOpoM. 2020.

449 4. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and 450 pathogenesis. *Methods Mol Biol.* 2015;1282:1-23.

451 5. Coronaviridae Study Group of the International Committee on Taxonomy of V.
452 The species Severe acute respiratory syndrome-related coronavirus: classifying
453 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol.* 2020;5(4):536-544.

454 6. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-455 nCoV on the epithelial cells of oral mucosa. *Int J Oral Sci*. 2020;12(1):8.

456 7. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 457 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med*. 2005;11(8):875-879.

458 8. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 459 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.

460 9. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. *J Clin Invest.* 461 2020;130(5):2202-2205.

- 462 10. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized
 463 Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*.
 464 2020.
- 465 11. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm 466 syndromes and immunosuppression. *Lancet*. 2020;395(10229):1033-1034.
- 467 12. Meredith Wadman JC-F, Jocelyn Kaiser, Catherine Matacic. How does 468 coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to 469 toes. 2020.
- 470 13. Vulliamy P, Jacob S, Davenport RA. Acute aorto-iliac and mesenteric arterial
 471 thromboses as presenting features of COVID-19. *Br J Haematol.* 2020.

472 14. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and 473 anticoagulation. *Blood.* 2020.

474 15. Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous
475 thromboembolic events in anticoagulated severe COVID-19 patients. *J Thromb*476 *Haemost.* 2020.

477 16. Lodigiani C, lapichino G, Carenzo L, et al. Venous and arterial
478 thromboembolic complications in COVID-19 patients admitted to an academic
479 hospital in Milan, Italy. *Thromb Res.* 2020;191:9-14.

480 17. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID and Coagulation:
481 Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection. *Blood*. 2020.

482 18. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are
483 associated with poor prognosis in patients with novel coronavirus pneumonia. J
484 Thromb Haemost. 2020;18(4):844-847.

485 19. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or
486 Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and
487 Follow-up. *J Am Coll Cardiol.* 2020.

488 20. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis
489 in patients with COVID-19. *Lancet Haematol.* 2020;7(6):e438-e440.

Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically III
 Patients With COVID-19 in Washington State. *JAMA*. 2020.

- 492 22. Yang X, Yang Q, Wang Y, et al. Thrombocytopenia and its association with 493 mortality in patients with COVID-19. *J Thromb Haemost*. 2020.
- Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe
 coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clin Chim Acta*.
 2020;506:145-148.

497 24. Lippi G, Favaloro EJ. D-dimer is Associated with Severity of Coronavirus
498 Disease 2019: A Pooled Analysis. *Thromb Haemost*. 2020.

- 499 25. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients.
 500 Ann Hematol. 2020;99(6):1205-1208.
- 501 26. Liu Y, Sun W, Guo Y, et al. Association between platelet parameters and 502 mortality in coronavirus disease 2019: Retrospective cohort study. *Platelets*. 503 2020;31(4):490-496.
- 504 27. Machlus KR, Italiano JE, Jr. The incredible journey: From megakaryocyte 505 development to platelet formation. *J Cell Biol.* 2013;201(6):785-796.
- 506 28. Lefrancais E, Ortiz-Munoz G, Caudrillier A, et al. The lung is a site of platelet 507 biogenesis and a reservoir for haematopoietic progenitors. *Nature*. 508 2017;544(7648):105-109.
- 509 29. Davi G, Patrono C. Platelet activation and atherothrombosis. *N Engl J Med.* 510 2007;357(24):2482-2494.
- 511 30. Ridger VC, Boulanger CM, Angelillo-Scherrer A, et al. Microvesicles in 512 vascular homeostasis and diseases. Position Paper of the European Society of 513 Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology. *Thromb* 514 *Haemost.* 2017;117(7):1296-1316.
- 515 31. Semple JW, Italiano JE, Freedman J. Platelets and the immune continuum. 516 *Nat Rev Immunol.* 2011;11(4):264-274.
- 517 32. Rick Kapur AZ, Eric Boilard, and John W. Semple. Nouvelle Cuisine: Platelets 518 Served with Inflammation. *J Immunol.* 2015;12(194).
- 519 33. Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for 520 platelets as immune and inflammatory cells. *Blood*. 2014;123(18):2759-2767.
- 521 34. Sreeramkumar V, Adrover JM, Ballesteros I, et al. Neutrophils scan for 522 activated platelets to initiate inflammation. *Science*. 2014;346(6214):1234-1238.
- 35. Imhof BA, Jemelin S, Ballet R, et al. CCN1/CYR61-mediated meticulous
 patrolling by Ly6Clow monocytes fuels vascular inflammation. *Proc Natl Acad Sci U*S A. 2016;113(33):E4847-4856.
- 526 36. Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. 527 *JCI Insight*. 2020.
- 528 37. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of 529 COVID-19: Neutrophil extracellular traps. *J Exp Med*. 2020;217(6).
- 530 38. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. *Blood*. 531 2014;123(18):2768-2776.
- 39. Constantinescu-Bercu A, Grassi L, Frontini M, Salles C, II, Woollard K,
 Crawley JT. Activated alphallbbeta3 on platelets mediates flow-dependent NETosis
 via SLC44A2. *Elife*. 2020;9.
- 535 40. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate 536 inflammatory signaling by regulated interleukin 1beta synthesis. *J Cell Biol.* 537 2001;154(3):485-490.
- 41. Karas SP, Rosse WF, Kurlander RJ. Characterization of the IgG-Fc receptor on human platelets. *Blood.* 1982;60(6):1277-1282.

42. Campbell RA, Schwertz H, Hottz ED, et al. Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3. *Blood*. 2019;133(19):2013-2026.

43. Simon AY, Sutherland MR, Pryzdial EL. Dengue virus binding and replication by platelets. *Blood*. 2015;126(3):378-385.

545 44. Koupenova M, Corkrey HA, Vitseva O, et al. The role of platelets in mediating 546 a response to human influenza infection. *Nat Commun.* 2019;10(1):1780.

- 45. Le VB, Schneider JG, Boergeling Y, et al. Platelet activation and aggregation
 promote lung inflammation and influenza virus pathogenesis. *Am J Respir Crit Care Med.* 2015;191(7):804-819.
- 46. Cloutier N, Allaeys I, Marcoux G, et al. Platelets release pathogenic serotonin
 and return to circulation after immune complex-mediated sequestration. *Proc Natl Acad Sci U S A*. 2018;115(7):E1550-E1559.
- 553 47. Boilard E, Pare G, Rousseau M, et al. Influenza virus H1N1 activates platelets 554 through FcgammaRIIA signaling and thrombin generation. *Blood.* 555 2014;123(18):2854-2863.
- 48. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med*. 2019;200(7):e45-e67.
- 49. Bou Khzam L, Hachem A, Zaid Y, Boulahya R, Mourad W, Merhi Y. Soluble CD40 ligand impairs the anti-platelet function of peripheral blood angiogenic outgrowth cells via increased production of reactive oxygen species. *Thromb Haemost.* 2013;109(5):940-947.
- 564 50. Hachem A, Yacoub D, Zaid Y, Mourad W, Merhi Y. Involvement of nuclear 565 factor kappaB in platelet CD40 signaling. *Biochem Biophys Res Commun.* 566 2012;425(1):58-63.
- 567 51. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is 568 an essential regulator of heart function. *Nature*. 2002;417(6891):822-828.
- 569 52. Danilczyk U, Penninger JM. Angiotensin-converting enzyme II in the heart and 570 the kidney. *Circ Res.* 2006;98(4):463-471.
- 571 53. Chen Y, Chen L, Deng Q, et al. The presence of SARS-CoV-2 RNA in the 572 feces of COVID-19 patients. *J Med Virol*. 2020.
- 573 54. Perry MJ, Arrington S, Neumann LM, Carrell D, Mores CN. It is currently 574 unknown whether SARS-CoV-2 is viable in semen or whether COVID-19 damages 575 sperm. *Andrology*. 2020.
- 576 55. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. *Blood*. 2003;101(10):3765-3777.
- 578 56. Dolmatova EV, Wang K, Mandavilli R, Griendling KK. The effects of sepsis on 579 endothelium and clinical implications. *Cardiovasc Res.* 2020.
- 580 57. Denis MM, Tolley ND, Bunting M, et al. Escaping the nuclear confines: signal-581 dependent pre-mRNA splicing in anucleate platelets. *Cell*. 2005;122(3):379-391.
- 582 58. Melki I, Tessandier N, Zufferey A, Boilard E. Platelet microvesicles in health 583 and disease. *Platelets*. 2017;28(3):214-221.
- 584 59. Owens AP, 3rd, Mackman N. Microparticles in hemostasis and thrombosis. 585 *Circ Res.* 2011;108(10):1284-1297.
- 586 60. Zaid Y, Senhaji N, Darif Y, Kojok K, Oudghiri M, Naya A. Distinctive roles of
- 587 PKC delta isozyme in platelet function. *Curr Res Transl Med.* 2016;64(3):135-139.

588 61. Murugappan S, Tuluc F, Dorsam RT, Shankar H, Kunapuli SP. Differential 589 role of protein kinase C delta isoform in agonist-induced dense granule secretion in 590 human platelets. *J Biol Chem*. 2004;279(4):2360-2367.

591 62. Buchholz UJ, Bukreyev A, Yang L, et al. Contributions of the structural 592 proteins of severe acute respiratory syndrome coronavirus to protective immunity. 593 *Proc Natl Acad Sci U S A*. 2004;101(26):9804-9809.

594 63. Koupenova M, Vitseva O, MacKay CR, et al. Platelet-TLR7 mediates host 595 survival and platelet count during viral infection in the absence of platelet-dependent 596 thrombosis. *Blood*. 2014;124(5):791-802.

- 597 64. Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 Infections in 598 Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. *Cell*. 599 2020;181(4):905-913 e907.
- 600 65. Duerschmied D, Suidan GL, Demers M, et al. Platelet serotonin promotes the 601 recruitment of neutrophils to sites of acute inflammation in mice. *Blood*. 602 2013;121(6):1008-1015.
- 603 66. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a 604 beta3 integrin--dependent mechanism. *Nat Med.* 2002;8(3):247-252.
- 605 67. Nunez-Avellaneda D, Mosso-Pani MA, Sanchez-Torres LE, Castro-Mussot 606 ME, Corona-de la Pena NA, Salazar MI. Dengue Virus Induces the Release of 607 sCD40L and Changes in Levels of Membranal CD42b and CD40L Molecules in 608 Human Platelets. *Viruses*. 2018;10(7).
- 609 68. Boudreau LH, Duchez AC, Cloutier N, et al. Platelets release mitochondria 610 serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote 611 inflammation. *Blood*. 2014;124(14):2173-2183.
- 612 69. Maugeri N, Capobianco A, Rovere-Querini P, et al. Platelet microparticles 613 sustain autophagy-associated activation of neutrophils in systemic sclerosis. *Sci* 614 *Transl Med*. 2018;10(451).
- 615

Tables

Table 1. Clinical Analysis and Blood Parameters.ALT = Alanine Transaminase; AST = Aspartate Transaminase; LDH = Lactate

Dehydrogenase

Indox	Patients wit	Р	
Index	Non-severe	Severe	value
Female/Male	32/39	12/22	
SARS-CoV-2 E gene (ct), detection (mean \pm SD)	27.44 ± 5.118	28.74 ± 6.141	0.2573
Age (mean ± SD), years	48.96 ± 17.96	57.15 ± 23.10	0.0325
Duration of hospitalization (mean \pm SD), days	14.37 ± 4.691	22.53 ± 10.62	<0.0001
Platelet value at admission (mean \pm SD), $\times 10^{6}$ /mL	208 ± 99.4	148.5 ± 101.1	0.0011
Lymphocyte value at admission (mean ± SD), ×10 ⁶ /mL	1.169 ± 0.8473	1.227 ± 0.8824	0.9443
Platelet-Lymphocyte Ratio at admission (mean ± SD)	420.2 ± 845.8	162.0 ± 111.1	0.0239
ALT value at admission (mean \pm SD), U/L	33.85 ± 14.92	37.77 ± 13.33	0.1844
AST value at admission (mean \pm SD), U/L	41.37 ± 17.81	42.65 ± 15.78	0.8983
LDH value at admission (mean ± SD), U/L	508.9 ± 236.9	695.4 ± 285.6	0.0015
622			•

Table 2. Detection of SARS-CoV-2 and ACE2 (mRNA) in platelets.ACE2 = Angiotensin-converting enzyme 2; ct = threshold cycle

Index			Patients with COVID-19	
		Healthy	Non-Severe	Severe
SARS-CoV-2 E gene	detection in platelets (positive/total donors)	0/17	9/38	2/11
	ct values (mean ± SD)	n.d.	28.89 ± 5.86	34 ± 2.82
ACE2, mRNA	detection in platelets (positive/total donors)	10/10	10/10	10/10
	ct values (mean ± SD)	27.73 ± 1.41	26.43 ± 0.53	26.93 ± 0.34

Figure 1 Cytokines in Plasma values indicate changes of cytokine levels



631

Figure 1. Cytokine and chemokine levels in plasma from COVID-19 patients. 632 Heat map visualization of 48 cytokine/chemokine expression profiles in plasma of 633 COVID-19 non-severe (mean of n=10) and severe (mean of n=9) patients relatively 634 to the heathy controls (mean of n=10). Cytokine/chemokine expression is 635 represented as a (log2) fold change relative to healthy controls. The numbers in 636 each panel represent the mean change and the color codes refer to red for 637 expression blue for decreased Absolute 638 increased and expression. cytokine/chemokine values (pg/mL) and statistical analysis are shown in Online 639 Figure VI. 640



Figure 2. Platelets are prone to produce and release inflammatory molecules in 642 **COVID-19 patients.** A) Platelets from healthy controls (n=9), COVID-19 non-severe 643 (n=9) and COVID-19 severe (n=9) patients were stimulated with 0.025, 0.05 or 2 644 U/mL of α -thrombin. Thromboxane B2 (TxB2), interleukin (IL)-18, IL-1 β and soluble 645 CD40 ligand (sCD40L) production was evaluated. Data are represented as mean ± 646 SD. Statistical analysis: one-way ANOVA. ***P<0.001 and ****P<0.0001. B) Heat 647 map visualization of 39 cytokine/chemokine expression profiles in platelet content of 648 COVID-19 non-severe (mean of n=10) or severe (mean of n=9) patients compared to 649 the heathy controls (mean of n=9). Cytokine/chemokine expression is represented as 650 a (log2) fold change relative to healthy controls. The numbers in each panel 651 represent the mean change and the color codes refer to red for increase expression 652 and blue for decrease expression. Absolute cytokine/chemokine values (pg/mL) and 653 statistical analysis are shown in **Online Figure VI**. 654

Figure 3



656

Figure 3. Platelets are degranulated in COVID-19 patients. Markers of platelet 657 degranulation (PF4 for alpha granules and serotonin for dense granules) were 658 evaluated in plasma of COVID-19 patients. Concentrations of PF4 (upper panels) 659 and serotonin (lower panels) were measured in platelets (A) and plasma (B) from 660 healthy controls, COVID-19 non-severe and COVID-19 severe patients. For platelet 661 content, values were expressed as ng per million platelets. Data are represented as 662 mean ± SD. Statistical analysis: ROUT method identified two outliers for serotonin 663 (platelet content), which were thus excluded from the analysis. one-way ANOVA. 664 **P<0.01,***P<0.001 ****P<0.0001, ns (non-significant). PF4: healthy controls (n=12 665 for plasma, n=10 for platelet content), COVID-19 non-severe (n=55 for plasma, n=10 666 for platelet content), COVID-19 severe (plasma n=31, platelet content n=9). 667 Serotonin: healthy controls (n=10 for plasma, n=10 for platelet content), COVID-19 668 non-severe (n=18 for plasma, n=9 for platelet content), COVID-19 severe (plasma 669 n=14, platelet content n=8). 670

Figure 4



Figure 4. Platelet extracellular vesicles are released in COVID-19 patients. 671 Circulating platelet extracellular vesicles (CD41+ EV) expressing phosphatidylserine 672 or not were analyzed in plasma from healthy controls (n=12), COVID-19 non-severe 673 (n=51) and COVID-19 severe patients (n=30). A) Total CD41+ EV were quantified 674 (left panel) and representative scatter plots of CD41+ EV relative size and inner 675 complexity (FSC=forward scatter, SSC=sideward scatter) are illustrated (right 676 677 panels). B) Annexin V+ CD41+ EV were quantified (left panel) and representative scatter plots of AnV+CD41+ EV relative size are illustrated (right panels). The gating 678 strategy is illustrated in **Online Figure VII**. Data are represented as mean ± SD. 679 Statistical analysis: Data were not normally distributed (Shapiro-Wilk test). Kruskal-680 Wallis test *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. 681



Figure 5. PKCδ phosphorylation is increased in platelets of COVID-19 patients. 682 PKCδ phosphorylation on Tyr311 residue is increased in response to α-thrombin in 683 patients with severe and non-severe COVID-19 infection. Platelets were stimulated 684 (or not) with 0.05 U/mL of α -thrombin for 5 min. Platelet lysates were analyzed by 685 SDS-PAGE for p-PKCo Tyr311. Total PKCo was evaluated in each condition. A) 686 Immunoblot representative of 3 donors. B) Densitometric analysis of p-PKCo Tyr311 687 normalized to total PKCo was performed, data were expressed as relative Optical 688 Density (n=3). Data are represented as mean ± SD. Statistical analysis: one-way 689 ANOVA. **P<0.01, ***P<0.001 and ****P<0.0001. 690



692

Figure 6. Platelets are prone to aggregation in COVID-19 patients. Platelet 693 aggregation and adhesion were evaluated in healthy donors, COVID-19 non-severe 694 and COVID-19 severe patients (n=9). A), B) Platelets were stimulated with 0.025, 695 0.05 or 2 U/mL. A) Representation of light transmission curve of platelets 696 aggregation from healthy controls and COVID-19 patients. B) Quantification (%) of 697 platelet aggregation in healthy controls (n=9), COVID-19 non-severe (n=9) or 698 COVID-19 severe (n=9) patients. C) Platelet adhesion on collagen was evaluated 699 under flow condition after 5 min. Data are presented as percentage of surface 700 covered by platelets. A representative image for each condition is illustrated. Data 701 are represented as mean ± SD. Statistical analysis: one-way ANOVA. **P<0.001. 702 703



705

- 706 Figure 7. Graphical Summary.
- 707 Novelty and Significance
- 708 a. What is known?

In addition to the overwhelming inflammation that prevails in COVID-19,
hypercoagulation and thrombosis are now recognized hallmark of severe COVID-19
and contribute to the lethality of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). Platelets are chiefly implicated in thrombosis and can interact with
different microbes including viruses. Moreover, platelets are a major source of
inflammatory mediators.

b. What new information does this article contribute?

This article documents that human platelets, in some patients (approximately 20%), contain SARS-CoV-2 RNA molecules. Moreover, platelets are hyperactivated in COVID-19: they have enhanced adhesion properties, degranulate (alpha and dense granule), and are a source of inflammatory cytokines and of extracellular vesicles. The data suggest that platelets could participate in the dissemination of SARS-CoV-2 and in the overwhelming thrombo-inflammation observed in COVID-19. Thus, blockade of platelet activation pathways may improve outcomes in this disease.